Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by chrispion Feb 17, 2021 11:18am
154 Views
Post# 32584514

RE:We're still...

RE:We're still...
working through the new shares that were issued on December 23rd as a result of the warrant conversion (see house # 2 RBC).

Hi barsax,
that would make logical sense but as I stated in a previous post 
https://stockhouse.com/companies/bullboard?symbol=v.bti&postid=32491216 it simply is not true that these shares being sold from RBC are from the warrant holders. The last two financings went into just a few hands. These are well-financed, strong hands and long-time supporters of the company and have no intention of flipping them for pennies. They’ve done their due diligence and realize the tremendous opportunity and $ upside. We have a market cap of $35m CDN. Regardless of what happened in the past, we are in the sweet spot for Bioasis RIGHT NOW … THIS YEAR. Lots and lots of upside here when you look at the HUGE markets in the disease indications they are pursuing.


<< Previous
Bullboard Posts
Next >>